EUVIMEDEUVIMED entdecken
Crossref

Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics

Wenyu Wu iD, Guoqiang Shao, Yilin Xue, Jun Chen, Zhaoyang Zhao, Jingjing Fu, Rui Yang, Hai Qian iD, Hanmei Xu iD

Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5946-5955

DOI: 10.1021/acs.molpharmaceut.6c01174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 14.10.2026. Verfasst von Wenyu Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing211198, China. Hauptthemen laut MEDLINE: Zirconium, Radioisotopes, Claudins, Lutetium. Die Arbeit nennt 18 Literaturangaben. Gefördert von: Nanjing Medical Science and Technology Development Fund, National Natural Science Foundation of China, Key Scientific Research Project (Natural Science Category), Department of Education of Anhui Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Claudin 18.2 (CLDN18.2) is a tight junction protein aberrantly expressed in gastric and pancreatic cancer. In this study, we developed the novel nanobody 18.2−50H and VHH-Fc fusion antibody 18.2−50C radiolabeled with 89Zr/177Lu for CLDN18.2-targeted radiotheranostics. Zolbetuximab (IMAB362), 18.2−50H, and 18.2−50C were conjugated with DFO and labeled with 89Zr, respectively. Radiochemical purity and in vitro stability were determined by radio-TLC. CLDN18.2-targeting specificity was evaluated using HEK-293T and HEK-293T/CLDN18.2 cells. PET/CT imaging and biodistribution studies were performed in mouse models and cynomolgus monkeys. Subsequently, 177Lu-DOTA-18.2-50C was prepared and assessed for tumor targeting in gastric cancer PDX models. 89Zr-DFO-IMAB362, 89Zr-DFO-18.2-50H, and 89Zr-DFO-18.2-50C were prepared with satisfactory radiochemical yield, specific activity, and stability. Tumors were clearly visible as early as 1 h post-injection of 89Zr-DFO-18.2-50H, with an uptake value of 9.07 ± 2.36 %ID/g and a tumor-to-muscle ratio of 27.35 ± 3.72. Fc-fused 89Zr-DFO-18.2-50C exhibited improved retention and higher tumor uptake than 89Zr-DFO-18.2-50H and 89Zr-DFO-IMAB362, with % ID/g increasing continuously from 5.07 ± 0.29 at 1 h to 32.95 ± 1.57 at 168 h. Notably, the introduction of the Fc chain also markedly increased the radiation exposure in the liver and spleen. Consistently, PET imaging in cynomolgus showed that 89Zr-DFO-18.2-50C is mainly concentrated in the liver, but no apparent abnormality was observed. Furthermore, 177Lu-DOTA-18.2-50C presented remarkable tumor selectivity with prolonged retention (16.92 ± 1.94 % ID/g at 5 d post-injection) in PDX models. Nanobody 89Zr-DFO-18.2-50H demonstrated a superior tumor-to-background ratio, positioning it as a promising tracer for detecting CLDN18.2-overexpressing lesions. 89Zr/177Lu-labeled VHH-Fc antibody 18.2−50C exhibited sustained higher tumor uptake than commercially available IMAB362 and provides a novel potential candidate for CLDN18.2-targeted radionuclide therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ZirconiumRadioisotopesClaudinsLutetiumRadiopharmaceuticalsStomach NeoplasmsSingle-Domain AntibodiesAnimalsHumansMiceTissue DistributionHEK293 CellsMacaca fascicularisCell Line, TumorPositron Emission Tomography Computed TomographyFemaleXenograft Model Antitumor Assays

Stichwörter der Autor:innen

89Zr/177LuCLDN18.2cynomolgusnanobodyradiotheranostics

Substanzen

ZirconiumRadioisotopesClaudinsZirconium-89LutetiumCLDN18 protein, humanRadiopharmaceuticalsLutetium-177Single-Domain Antibodies

Autor:innen und Institutionen

  • Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing211198, China.
  • Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing210006, China.
  • Jiangsu Province Engineering Research Center of Synthetic Peptide Drug Discovery and Evaluation, China Pharmaceutical University, Nanjing211198, China.
  • Department of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing211198, China.
  • Hui Ya Hospital of The First Affiliated Hospital, Sun Yat-sen University, Huizhou516000, China.
  • Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing211198, China.

ORCID-Profile: Wenyu Wu, Hai Qian, Hanmei Xu

Förderung

  • Nanjing Medical Science and Technology Development Fund
  • National Natural Science Foundation of China
  • Key Scientific Research Project (Natural Science Category), Department of Education of Anhui Province
  • Nanjing Health Technology Development Special Fund Project

Zitieren

APA

Wu, W., Shao, G., Xue, Y., Chen, J., Zhao, Z., Fu, J., Yang, R., Qian, H., & Xu, H. (2026). Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics. Molecular Pharmaceutics, 23(11), 5946-5955. https://doi.org/10.1021/acs.molpharmaceut.6c01174

Vancouver

Wu W, Shao G, Xue Y, Chen J, Zhao Z, Fu J, et al. Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics. Molecular Pharmaceutics. 2026;23(11):5946-5955. doi:10.1021/acs.molpharmaceut.6c01174

BibTeX
@article{Wu2026,
  author = {Wu, Wenyu and Shao, Guoqiang and Xue, Yilin and Chen, Jun and Zhao, Zhaoyang and Fu, Jingjing and Yang, Rui and Qian, Hai and Xu, Hanmei},
  title = {Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {11},
  pages = {5946--5955},
  doi = {10.1021/acs.molpharmaceut.6c01174}
}
Kostenlos starten →